Biosimilars
Biosimilars have similar, but not identical, structures to branded biologic drugs. Being comparable, but not interchangeable, they can differ in cost-effectiveness and accessibility. Increased competition, however, can reduce healthcare system costs.
What is the Role of HTA for Biosimilars?
1 April 2014
This Briefing summarises the results of a roundtable convened by OHE to discuss using HTA to assess biosimilars – including which methods are most appropriate in…
The Market for Biosimilars
25 January 2011
This publication expands on the series of posts published earlier on this blog. It reports on a seminar intended to encourage further thought about the distinguishing…
Estimating US Savings from Biosimilars
13 July 2010
The law signed in March 2010 eliminated some of the uncertainty about the future of biosimilars in the US. Still unclear is the impact biosimilars actually…
EU Approval of Biosimilars
8 July 2010
Biosimilar products in the European Union (EU) must go through a centralised procedure that licenses the product for use in EU Member States. Until experience grows…
Biosimilars’ Price Dynamic in Europe
30 June 2010
Europe already has some experience with the impact of biosimilars on pricing, including a price war in Germany for EPOs. Whether that experience will be repeated,…
Price Competition and Biosimilars
23 June 2010
Virtually all models forecast that price competition will be less intense and price declines modest in comparison to the generics model. Many models, however, miss or…
Biosimilars: Modelling the Evolution of the Market
16 June 2010
The OHE model varies from other models of biosimilar markets evolution by starting with transaction prices, rather than list prices, and factoring in the collection of…
Biosimilars and Data Exclusivity
8 June 2010
Data exclusivity is critical to ensuring that biosimilars achieve an appropriate balance between increasing market competition and encouraging innovation. The history of ‘traditional generics’ is a…
Biosimilars: Issues Overview
1 June 2010
This is the second in our series of posts based on the OHE seminar on biosimilars and summarises the remarks of Prof Bengt Jönsson of the…